Devices & Diagnostics

BSX scores FDA device approval for drug-eluting stent for coronary artery disease patients

Boston Scientific (BSX) received FDA device approval for its Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent […]

Boston Scientific (BSX) received FDA device approval for its Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, a next-gen polymer drug-eluting stent. The product launches immediately in the U.S. It will be used to treat patients with coronary artery disease.

The company boasts the system offers “unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, while improving axial strength and deliverability.” The delivery system has a shorter “more visible” tip.

According to the press release:

The Promus PREMIER Stent System offers physicians improved DES performance in treating patients with coronary artery disease, and features unique customized platinum chromium alloy stent architecture, the market-leading Everolimus drug with a biocompatible, fluorinated co-polymer and an enhanced stent delivery system.

The system is offered in 94 sizes, with varying diameters and lengths.

Compared to Boston Scientific’s competitors, the medical device company said the stent could save up to $116 a procedure (specifically with Abbott‘s (ABT) alternative–the Xience V Stent–in its crosshairs).

The stent received the CE Mark in February 2013.

Follow MedCity News on Facebook and Twitter for more updates.

Shares0
Shares0